National Pension Service Raises Stake in Gilead Sciences, Inc. $GILD

National Pension Service grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,370,643 shares of the biopharmaceutical company’s stock after acquiring an additional 109,230 shares during the quarter. National Pension Service owned about 0.27% of Gilead Sciences worth $374,141,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. RWWM Inc. purchased a new stake in shares of Gilead Sciences in the third quarter valued at about $796,000. Winnow Wealth LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $1,162,000. Bryn Mawr Trust Advisors LLC grew its stake in shares of Gilead Sciences by 20.2% in the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 3,461 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 581 shares during the period. Cornerstone Wealth Management LLC increased its holdings in shares of Gilead Sciences by 1.5% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 7,479 shares of the biopharmaceutical company’s stock worth $830,000 after buying an additional 113 shares during the last quarter. Finally, Significant Wealth Partners LLC raised its position in shares of Gilead Sciences by 12.4% during the 3rd quarter. Significant Wealth Partners LLC now owns 6,474 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 713 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GILD shares. Royal Bank Of Canada increased their price objective on Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research report on Tuesday, January 20th. Needham & Company LLC increased their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $136.36.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 257,397 shares of company stock worth $33,385,512 over the last three months. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Up 1.7%

Shares of NASDAQ:GILD opened at $141.95 on Friday. The firm has a market capitalization of $176.11 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $142.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm’s 50-day moving average is $125.36 and its two-hundred day moving average is $119.59.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.